CN109316483A - The medical usage of isochuanliansu - Google Patents
The medical usage of isochuanliansu Download PDFInfo
- Publication number
- CN109316483A CN109316483A CN201811280279.8A CN201811280279A CN109316483A CN 109316483 A CN109316483 A CN 109316483A CN 201811280279 A CN201811280279 A CN 201811280279A CN 109316483 A CN109316483 A CN 109316483A
- Authority
- CN
- China
- Prior art keywords
- isochuanliansu
- breast cancer
- cell
- tumor
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to medicines, more particularly to a kind of medical usage of isochuanliansu.Isochuanliansu of the invention can be used for preventing and treating breast cancer.
Description
Technical field
The present invention relates to field of medicaments, more particularly to a kind of medical usage of isochuanliansu.
Background technique
Malignant tumour is global common problem, all causes very big shadow to national economy, social development, people's health
It rings, tumor prevention has become the emphasis of global health strategy with control.The important feature of tumour cell is not can be carried out normally
Differentiation, start normal apoptotic process, therefore, development prevention and treatment tumour medicine will bring benefit to the mankind.
Breast cancer is disease incidence highest in women, the most common malignant tumour.The World Health Organization (WHO) international cancer is ground
Mechanism (International Agency for Research on Cancer, IARC) is studied carefully by collecting, storing up regularly
It deposits, arrange, analyze and evaluates the tumour registration data in the whole world and announce: global de novo malignancy case 14,090,000 in 2012,
Dead 8,200,000, global women has more than 1,670,000 breast cancer new cases, accounts for the head of women whole Incidence composition
Position, almost in every 4 female malignant cases, just having 1 is breast cancer case；The same period dies of the female patient of breast cancer
There are about 520,000, it also is located at the first place of female malignant causes of death.In recent years, the disease incidence of global women with breast cancer and
The situation that rises year by year is presented in mortality level, and accounts for global women whole Incidence, dead composition also
Increase.
Triple negative breast cancer is one kind more serious in breast cancer.Triple negative breast cancer refers to cancerous tissue immuning tissue
Inspection result is estrogen receptor (ER), progesterone receptor (PR) and proto-oncogene Her-2 are negative breast cancer.This
Class breast cancer accounts for the 10.0%~20.8% of all breast cancer histological types, has special biological behaviour and clinical pathology
Feature, prognosis is poor compared with other types, and mortality risk is higher.Triple negative breast cancer clinical manifestation is a kind of aggressive course of disease, remote
Place shifts risk higher, and for visceral metastases chance compared with Bone tumour height, brain metastes probability is also higher.The distant place of triple negative breast cancer turns
It moves risk to peak at 3 years, may be declined later.The prognosis of three negative breast cancer and tumor size and lymph node
Situational relationship is little, and recurrence is rapid.Due to a lack of the target spot that endocrine and anti-HER2 are treated, three are directed to there is presently no distinctive
The treatment guidelines of negative breast cancer, therefore its treatment is generally carried out by the treatment of breast cancer conventional criteria.
In cancer treatment, although traditional Radiotherapy chemotherapy has been achieved for very big progress, since it is thin in killing cancer
While born of the same parents, different degrees of toxic side effect is also generated to human body, wherein mainly bone marrow suppression and immunologic hypofunction, it can
Leukopenia etc. is caused, even has to interrupt treatment sometimes, to also limit the curative effect of drug.It is passed to overcome
A series of disadvantages brought by the Radiotherapy chemotherapy of system, pharmacy worker constantly explores in recent years, and exploitation is more safely and effectively
Botanical medicine, which carries out anti-curing cancers, becomes the hot fields of current research.
Fructus meliae toosendan is the dry mature fruit of Meliaceae plant melia toosendan MeLia toosendan Sieb.et Zucc., with " chinaberry
Name in fact " is distributed in the ground such as Henan, Gansu, Hunan, Guangxi, Sichuan, Guizhou, Yunnan first recorded in Shennong's Herbal more.Taste
Bitterness is cold, slightly poisonous, has purging intense heat, analgesic, insecticidal action, cures mainly stomachache, abdominal pain due to enterositosis, colic, dysmenorrhea etc..It is soothing the liver to expel the heat-evil,
Promoting qi circulation and relieving pain, desinsection.For liver depression forming fire, chest side of body, abdominal distention, hernia pain, abdominal pain due to enterositosis.Isochuanliansu
(Isotoosendanin, iso-chuanliansu) is the chinaberry alkane type triterpenoid class compound isolated and purified in Fructus meliae toosendan, right at present
The research of the pharmacological activity of isochuanliansu is still not clear.
Summary of the invention
The purpose of the present invention is intended to provide a kind of new medical usage of isochuanliansu.
Specifically, there is provided a kind of isochuanliansus in the drug of preparation prevention and treatment breast cancer for the first aspect of the present invention
Application.
In a preferred example, the isochuanliansu is the medicine that prevention and treatment breast cancer is used to prepare as unique active constituent
Object.
In another preferred example, the breast cancer is triple negative breast cancer.
A kind of the second aspect of the present invention answering in the drug of preparation prevention and treatment Metastasis in Breast Cancer there is provided isochuanliansu
With.
In a preferred example, the isochuanliansu is that prevention and treatment Metastasis in Breast Cancer is used to prepare as unique active constituent
Drug.
In another preferred example, the breast cancer is triple negative breast cancer.
The details of various aspects of the present invention will be able to detailed description in subsequent chapters.By hereafter and claim
Description, the features of the present invention, purpose and advantage will become apparent from.
Detailed description of the invention
Lethal effect of Fig. 1 isochuanliansu to a variety of breast cancer cells
(a)MDA-MB-231 (b)MCF-7 (c)4T1
Influence of Fig. 2 isochuanliansu medication to female Balb/c mouse 4T1 solid tumor
Influence of Fig. 3 isochuanliansu medication to female Balb/c 4T1 tumor-bearing mice Biochemical Indices In Serum
Inhibiting effect --- the scratch experiment result of Fig. 4 isochuanliansu medication breast cancer cell migration
(a)MDA-MB-231 (b)4T1
It is from left to right respectively model group, isochuanliansu low dose group, isochuanliansu middle dose group, the high agent of isochuanliansu
Amount group
The inhibiting effect of Fig. 5 isochuanliansu medication breast cancer cell migration --- cell migrates experimental result
(a)MDA-MB-231 (b)4T1
It is from top to bottom respectively model group, isochuanliansu low dose group, isochuanliansu middle dose group, the high agent of isochuanliansu
Amount group
Influence of Fig. 6 isochuanliansu medication to female Balb/c mouse 4T1 solid tumor
Influence of Fig. 7 isochuanliansu medication to the female Balb/c tumor-bearing mice 4T1 death rate
Influence-living imaging result of Fig. 8 isochuanliansu medication to female Balb/c mouse 4T1 entity tumor metastasis
Influence of Fig. 9 isochuanliansu medication to the female Balb/c mouse 4T1 solid tumor rate of transform
Influence-lung HE coloration result of Figure 10 isochuanliansu medication to female Balb/c mouse 4T1 entity tumor metastasis
A: blank group B: model group C: isochuanliansu 0.1mg/kg D: isochuanliansu 1mg/kg E:5- fluorouracil
Specific embodiment
Appearance part of the invention is had been surprisingly found that based on such a: isochuanliansu has most of tumours certain
Inhibiting effect, especially triple negative breast cancer.Therefore, which can be expected to be developed into a kind of prevention or three yin for the treatment of
The drug of property breast cancer.
In turn, the application the present invention provides isochuanliansu in the drug of preparation prevention and treatment breast cancer and Metastasis in Breast Cancer.
Isochuanliansu (Isotoosendanin, iso-chuanliansu) of the invention be colourless needle crystals, fusing point be 270~
273 DEG C, it is soluble in pyridine, is slightly soluble in methanol, acetone and dioxane, is insoluble in chloroform, benzene and water.The molecule of isochuanliansu
Formula is C30H38O11, structural formula is as follows:
Isochuanliansu of the invention can be obtained by commercial sources from Shanghai Yuan Ye Biotechnology Co., Ltd etc. purchase,
Also it is extracted and is obtained from Fructus meliae toosendan with the conventional method of this field, such as: Fructus meliae toosendan medicinal material is beaten into powder, with water, 20%~95%
The refluxing extractions such as ethyl alcohol, acetone, ethyl acetate, gasoline or petroleum ether are made.
Isochuanliansu of the invention can be used alone or be used in the form of pharmaceutical composition.Pharmaceutical composition includes making
For the isochuanliansu and pharmaceutical acceptable carrier of the invention of active constituent.Preferably, pharmaceutical composition of the invention contains 0.1-
The isochuanliansu of the invention as active constituent of 99.9% weight percent." pharmaceutical acceptable carrier " will not destroy the present invention
Isochuanliansu pharmaceutical active, while its effective dose, dosage when can play pharmaceutical carrier effect is nontoxic to the human body.
Described pharmaceutical acceptable carrier includes but is not limited to: soft phosphatide, aluminum stearate, aluminium oxide, ion exchange material, self-emulsifying
Drug delivery system, tween or other surfaces activator, haemocyanin, buffer substance for example phosphate, amion acetic acid, sorbic acid,
Water, salt, electrolyte such as sulfate protamine, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salt, magnesium silicate, saturated fatty acid
Partial glyceride mixtures etc..
Other common excipient substance such as adhesives (such as microcrystalline cellulose), filler (such as starch, glucose, anhydrous lactitol
Sugar and lactose bead), disintegrating agent (such as cross-linked pvp, crosslinked carboxymethyl fecula sodium, croscarmellose sodium, low substitution hydroxyl
Propyl cellulose), lubricant (such as magnesium stearate) and sorbefacient, absorption carrier, flavouring agent, sweetener, excipient,
Diluent, wetting agent etc..
Isochuanliansu of the invention and its pharmaceutical composition can be prepared by conventional method in that art and can pass through enteron aisle
Or non-bowel or topical routes.Oral preparation include capsule, tablet, oral solution, granule, pill, powder, sublimed preparation,
Paste etc.；Non-intestinal drug delivery agent includes injection etc.；Local administration preparation includes creme, patch, ointment, spray etc..
Preferably oral preparation.
The administration route of isochuanliansu of the invention and its pharmaceutical composition can for it is oral, sublingual, percutaneous, through muscle
Or subcutaneous, mucocutaneous, vein, urethra, vagina etc..
Present invention will be further explained below with reference to specific examples.It should be understood that these embodiments are merely to illustrate the present invention
Rather than it limits the scope of the invention.In the following examples, the experimental methods for specific conditions are not specified, usually according to conventional strip
Part or according to the normal condition proposed by manufacturer.Unless otherwise stated, otherwise all percentage, ratio, ratio or number
By weight.
Unless otherwise defined, it anticipates known to all professional and scientific terms as used herein and one skilled in the art
Justice is identical.In addition, any method similar to or equal to what is recorded and material can be applied to the method for the present invention.Text
Described in preferred implement methods and materials be for illustrative purposes only.
The feature that the features described above or embodiment that the present invention mentions are mentioned can be in any combination.Patent specification is taken off
All features shown can be used in combination with any composition form, and each feature disclosed in specification any can provide phase
The alternative characteristics of same, impartial or similar purpose replace.Therefore except there is special instruction, revealed feature is only impartial or phase
Like the general example of feature.
Lethal effect of 1. isochuanliansu of embodiment to a variety of breast cancer cells
The present invention has been primarily looked to be deposited with a variety of breast cancer cells that mtt assay detection isochuanliansu acts on different genera
The relationship of motility rate and isochuanliansu concentration.
Mtt assay is also known as MTT colorimetric method, is a kind of method for detecting cell survival and growth.Its testing principle is to utilize work
Intracellular mitochondrial dehydrogenase can convert Methyl thiazoly tetrazolium assay to the principle of bluish violet derivative first a ceremonial jade-ladle, used in libation to detect living cells
Number.With three agent (10%SDS-5% isobutanol -0.01M HCl) dissolution first a ceremonial jade-ladle, used in libation crystallization after, with microplate reader in 570nm with
Light absorption value is measured at 630nm.It can reflect living cells quantity indirectly.Within the scope of certain cell number, MTT crystallize the amount to be formed with
Cell number is directly proportional.
1.1 experimental material
1.1.1 cell strain
MDA-MB-231 cell strain；MCF-7 cell strain (Breast cancer lines)；(mouse breast cancer is thin for 4T1 cell strain
Born of the same parents' strain)
1.1.2 test medicine and its preparation
Isochuanliansu (is purchased from Shanghai source leaf biology Co., Ltd), is dissolved in the mother that 0.1M is made in DMSO (dimethyl sulfoxide)
Liquid.
1.1.3 main agents
DMEM, RPMI1640, fetal calf serum (GIBCO company), dimethyl sulfoxide (DMSO) (GIBCO company), MTT
(Sigma company), other reagents are pure etc. for domestic analysis.
1.1.4 key instrument equipment
Laminar flow super-clean bench；Carbon dioxide incubator is purchased from Thermo company；Inverted phase contrast microscope, it is public purchased from Olympus
Department；Microplate reader is purchased from Biotek company.
1.2 experimental method
The cells such as MCF-7, MDA-MB-231,4T1 are inoculated in 96 orifice plates with the cell density in 6000/hole, every hole
100 μ L of cell suspension, after about 12 hours when cell adherent growth is in good condition, be added various concentration ITSN (0,0.1,
0.3, 1,3,10μM).After 48h, every hole is added 10 μ L MTT (final concentration of 0.5mg/ml), 5% in 37 DEG C of cell incubators
After being incubated for 4h under the conditions of CO2, three agent, 50 μ L dissolution first a ceremonial jade-ladle, used in libation crystallization is added.Reaction 12h is placed on microplate reader, read 570nm with
Absorbance value (OD) at 630nm.Administration group is set to cell survival rate divided by the value of control group, according to the following formula:
Cell survival rate (%)=administration group OD (570nm-630nm)/control group OD (570nm-630nm) × 100%
1.3 statistical procedures
Experimental data uses average value ± standard error to indicate, is analyzed with SPSS17.0 statistical software, with One-Way
ANOVA mode carries out variance analysis, and P < 0.05 is with statistical significant difference standard.
1.4 experimental result
As shown in Figure 1, isochuanliansu can significantly inhibit human breast cancer cell line Bcap-37, MDA-MB-231, mouse in the present invention
The growth of breast cancer cell 4T1 prompts isochuanliansu to can be used for the treatment of a variety of breast cancer.In addition to this, human breast cancer cell
MDA-MB-231 and mouse mastopathy cell 4T1 is triple negative breast cancer cell line, and MCF-7 is ER positive breast cancer cell lines,
From the point of view of MTT experiment result, under same a dosage, isochuanliansu is significantly greater than the lethal effect of triple negative breast cancer cell
Non- triple negative breast cancer cell line prompts isochuanliansu to can be used as the therapeutic agent of potential triple negative breast cancer.
Influence of 1 isochuanliansu of table to the growth (%) of a variety of breast cancer cells
Compared with blank group, P < 0.001 * * P < 0.01, * * *
The internal anti-triple negative breast cancer solid tumor effect of 2. isochuanliansu of embodiment
After being determined that isochuanliansu has stronger lethal effect to these types of breast cancer cell in vitro, especially
After being determined that isochuanliansu has extremely strong lethal effect to triple negative breast cancer cell line in vitro, the present invention is further first
The internal anti-triple negative breast cancer solid tumor effect of isochuanliansu of the present invention is investigated.
2.1 experimental material
2.1.1 animal subject
Female Balb/c mouse
2.1.2 test medicine and its preparation
Isochuanliansu is dissolved in 0.5%CMC-Na (sodium carboxymethylcellulose) solution.5-Fu (Shanghai nation at) is dissolved in physiology salt
In water.
2.2 experimental method
2.2.1 tumor-bearing mice anti-tumor experiment in body
Using tumor-bearing mice experiment in vivo, a certain number of 4T1 cells are cultivated, centrifugation removal pancreatin, serum-free after digestion
Culture medium, which is resuspended, to be counted, and is diluted to 1.0 × 107Cells/mL is inserted on ice, it is dense that subcutaneous injection (sc) is inoculated with this in centrifuge tube
Tumour cell is spent under Balb/c mouse right axillary, and injection volume 0.1mL/ is only.It is grouped at random by weight, respectively model group
(0.5%CMC-Na), positive drug 5 FU 5 fluorouracil group, isochuanliansu low dose group (1mg/kg), isochuanliansu high dose group
(3mg/kg).Drug is dissolved to required concentration with 0.5%CMC-Na, 3 weeks after inoculation start by the daily stomach-filling of weight (ig)
Administration, model group ig give the 0.5%CMC-Na of equal volume, and 5 FU 5 fluorouracil (being dissolved to 2.5mg/mL with dd water) organizes abdomen
Chamber injects (ip), and every other day injection is primary；Successive administration 14d.Vernier caliper measurement knurl footpath is used every other week, and record is external
The length and width (mm) of tumor.After the last administration for 24 hours, eyeball blood sampling is plucked, for measuring Serum ALT and AST vigor after centrifuge separation serum
With；Tumor tissue is taken, weighs, takes pictures.It presses formula and calculates gross tumor volume (Tumor volumn) and tumor control rate (Tumor
inhibition ratio)。
Tumor volumn(mm3)=a*b*b/2, wherein a refers to the length of tumor, and b refers to the width of tumor.With knurl product and model
Group has significant difference, and P < 0.05 is drug standard with anti-tumor activity.
Tumor inhibition ratio (%)=[(C-T)/C] × 100, wherein C refers to that CMC-Na control group is averaged tumor
Volume, T refer to administration group average external volume.There is significant difference with knurl product, and tumor control rate > 30% is that drug has anti-swell
The standard of tumor activity.
2.3 statistical procedures
Experimental data uses average value ± standard error to indicate, is analyzed with SPSS17.0 statistical software, with One-Way
ANOVA mode carries out variance analysis, and P < 0.05 is with statistical significant difference standard.
2.4 experimental result
2.4.1 influence of the isochuanliansu medication to female Balb/c mouse 4T1 solid tumor
Compared with model group, as shown in table 2, Fig. 2, the mouse of 4T1 is inoculated with after continuously giving ITSN (1mg/kg) 14d,
Knurl product is substantially reduced (P < 0.05), shows that ITSN (1mg/kg) is effective to 4T1 solid tumor, and tumor control rate is more than 30%,
Show that isochuanliansu has significant anti-triple negative breast cancer activity in vivo.More relative to 5-Fu group isochuanliansu dosage
It is low, and antitumous effect is close, shows that the anti-triple negative breast cancer of isochuanliansu of the present invention has some superiority on dosage.
Influence of the 2 isochuanliansu medication of table to female Balb/c mouse 4T1 solid tumor
Compared with model group, P < 0.05 *
2.4.2 to the influence of Biochemical Indices In Serum
By table 3, Fig. 3 it is found that isochuanliansu medication group to tumor-bearing mice without significant hepatotoxicity wind agitation, prompt different melia toosendan in the present invention
Element has no significant effect hepatic injury index while keeping curative effect, illustrates isochuanliansu of the present invention in antitumor dose not
Apparent hepatic injury can be induced.
Influence of the 3 isochuanliansu medication of table to female Balb/c 4T1 tumor-bearing mice Biochemical Indices In Serum
3. isochuanliansu of embodiment acts on the inhibition of metastasis of a variety of breast cancer cells
After being determined that isochuanliansu has stronger lethal effect to these types of breast cancer cell in vitro, the present invention
The effect that the low dosage of isochuanliansu of the present invention inhibits triple negative breast cancer cell line to migrate in vitro has further been investigated first.
3.1 experimental material
3.1.1 cell strain
MDA-MB-231 cell strain (Breast cancer lines)
4T1 cell strain (mouse mastopathy cell strain)
3.1.2 test medicine and its preparation
Isochuanliansu (is purchased from Shanghai source leaf biology Co., Ltd), is dissolved in the mother that 0.1M is made in DMSO (dimethyl sulfoxide)
Liquid.
3.1.3 main agents
RPMI1640, fetal calf serum (GIBCO company), dimethyl sulfoxide (DMSO) (GIBCO company), crystal violet solution
(Life company), other reagents are pure etc. for domestic analysis.
3.1.4 key instrument equipment
Laminar flow super-clean bench；Carbon dioxide incubator is purchased from Thermo company；Inverted phase contrast microscope, Olympus IX81
Fluorescence microscope is purchased from Olympus company；Microplate reader is purchased from Biotek company；Camera is purchased from Nikon company.
3.2 experimental method
3.2.1MDA-MB-231,4T1 cell scratch experiment
After the cells such as MDA-MB-231,4T1 are digested with pancreatin, it is 3 × 10 that density, which is made, in resuspension5The cell of a/mL is outstanding
Liquid is inoculated in 24 orifice plates, every hole cell suspension 1mL.Uniform adherent and cell confluency sucks original at 90% or more
Culture medium is added 200 μ L of DPBS and cleans remaining culture medium, adds 200 μ L DPBS.With 200 μ L pipette tips after sterilizing
The rapid standardized road straight line in board bottom center again, after the cell to fall off is washed away, repetition is cleaned twice with DPBS, and every hole is added and is free of
The culture medium 1mL of FBS, administration group be separately added into various dose isochuanliansu (MDA-MB-231:100nM, 300nM,
1000nM；4T1:10nM, 30nM, 100nM).The visual field every hole Qu Liangge is worked with cellSens Dimension Image Acquisition
It stands and records the width of scratch, with marking pen mark position at shooting.Respectively 0h after the dosing of shot mark position, for 24 hours, 48h scratch
Change width, record data, calculate versus cell mobility (Migration percentage).Versus cell mobility
Difference and the ratio of control group scratch width, the formula for being defined as each time point control group and administration group scratch width are as follows:
Migration percentage (%)=(administration group scratch width-control group scratch width)/control group scratch
Width × 100% 3.2.2MDA-MB-231,4T1 Cell migration assay
Stand-type cell is placed in 24 orifice plates, cell 0.5% gelatin, 37 DEG C of coating 30min are small by starvation one in advance
When cell dissociation get off after, with without serum RPMI1640 culture medium resuspension be made density be 1.5 × 105A/ml cell
Suspension.By the cells such as MDA-MB-231,4T1 use respectively various concentration isochuanliansu (MDA-MB-231:100nM, 300nM,
1000nM；4T1:10nM, 30nM, 100nM) in advance incubate 15min after be inoculated in cell, each 100 μ L of cell cell suspension, under
The RPMI1640 culture medium that 600 μ L contain 10% fetal calf serum is added in room.After for 24 hours, the culture medium for the room cell Zhong Jixia that exhausts, often
The methanol 1mL of -20 DEG C of pre-coolings in advance are added in hole, and the methanol that exhausts is fixed after 30min in -20 DEG C of refrigerators, and cell is taken out and is inverted
It dries, dyes 15min with 0.1% crystal violet solution.Violet staining liquid is washed away in PBS solution again, the cell of chamber is used
Wet cotton swab is wiped, and shoots the cell that cell bottom is dyed to purple, each cell after drying under inverted phase contrast microscope
5 visuals field are taken, are taken pictures.Cell is placed in 33% glacial acetic acid solution after taking pictures, eluent is transferred in 96 orifice plates, is read
Absorbance value (OD) at 570nm.The difference that control group subtracts administration group is set to cellular migration inhibition rate divided by the value of control group, presses
Following formula calculate:
Cellular migration inhibition rate (%)=(administration group OD value-control group OD value)/control group OD value × 100%
3.3 statistical procedures
Experimental data uses average value ± standard error to indicate, is analyzed with SPSS17.0 statistical software, with One-Way
ANOVA mode carries out variance analysis, and P < 0.05 is with statistical significant difference standard.
3.4 experimental result
3.4.1 isochuanliansu inhibits MDA-MB-231,4T1 cell migration --- scratch experiment result
Scratch result such as table 4, Fig. 4 are shown, after going administration with the dosage of no overt toxicity, middle high two dosage group cells
Distance of creeping is obviously shortened, and illustrates that isochuanliansu obviously inhibits cell migration, and isochuanliansu is prompted to have certain three yin of inhibition
Property breast cancer cell migration effect.
The influence that 4 isochuanliansu medication 48h of table migrates triple negative breast cancer cell MDA-MB-231 and 4T1-scratch is real
Test result
3.4.2 isochuanliansu inhibits MDA-MB-231,4T1 cell migration --- and cell migrates experimental result
Cell migration results such as table 5, Fig. 5 are shown, after the dosage administration of no overt toxicity, the different river of middle high two dosage
In the visual field of chinaberry element, the cell of migration is significantly reduced, and isochuanliansu is prompted to have certain inhibition triple negative breast cancer cell migration
Effect.
5 isochuanliansu medication 48h of table moves the influence-cell migrated triple negative breast cancer cell MDA-MB-231 and 4T1
Move experimental result
The internal anti-breast cancer cancer solid tumor transferance of 4. isochuanliansu of embodiment
After being determined that isochuanliansu has stronger lethal effect to these types of tumour cell in vitro, the present invention is first
The internal inhibition breast cancer cell transferance of isochuanliansu of the present invention is first further investigated.
4.1 experimental material
4.1.1 animal subject
Female Balb/c mouse
4.1.2 test medicine and its preparation
Isochuanliansu is dissolved in 0.5%CMC-Na (sodium carboxymethylcellulose) solution.5-Fu (Shanghai nation at) is dissolved in physiology salt
In water.
4.2 experimental method
4.2.1 tumor-bearing mice anti-tumor experiment in body
Using tumor-bearing mice experiment in vivo, a certain number of inoculation 4T1-Luc-GFP cells are cultivated, removal is centrifuged after digestion
Pancreatin, serum free medium, which is resuspended, to be counted, and is diluted to 1.0 × 107Cells/mL inserts subcutaneous injection on ice in centrifuge tube
(sc) the concentration tumour cell is inoculated under the #4 cream lift of Balb/c mouse left side at 2mm, and injection volume 0.1mL/ is only.By weight
Random grouping, respectively Model (0.5%CMC-Na), 5-Fu, isochuanliansu low dose group (0.1mg/kg), isochuanliansu are high
Dosage group (1mg/kg).Drug is dissolved to required concentration with 0.5%CMC-Na, 1 week after inoculation starts to fill daily by weight
Stomach (ig) administration, Model group ig give the 0.5%CMC-Na of equal volume, and 5-Fu (being dissolved to 2.5mg/mL with dd water) organizes abdomen
Chamber injects (ip), and every other day injection is primary；Successive administration 5 weeks.A living imaging experiment is carried out weekly within 2 weeks after inoculation, see
It examines and whether shifts.With vernier caliper measurement knurl footpath, the length of external tumor and wide (mm) is recorded within every 3 days.After the last administration for 24 hours,
Eyeball blood sampling is plucked, for measuring Serum ALT and AST vigor after centrifuge separation serum；Tumor tissue is taken, lung is taken, takes liver, is taken by cancer
Tissue, weighing, takes pictures, and observes lung, the whether effective tumor nodule stove of liver.It presses formula and calculates gross tumor volume (Tumor
Volumn) with tumor control rate (Tumor inhibition ratio).
Tumor volumn(mm3)=a*b*b/2, wherein a refers to the length of tumor, and b refers to the width of tumor.With knurl product and model
Group has significant difference, and P < 0.05 is drug standard with anti-tumor activity.
Tumor inhibition ratio (%)=[(C-T)/C] × 100, wherein C refers to that CMC-Na control group is averaged tumor
Volume, T refer to administration group average external volume.There is significant difference with knurl product, and tumor control rate > 30% is that drug has anti-swell
The standard of tumor activity.
4.3 statistical procedures
Experimental data uses average value ± standard error to indicate, is analyzed with SPSS17.0 statistical software, with One-Way
ANOVA mode carries out variance analysis, and P < 0.05 is with statistical significant difference standard.
4.4 experimental result
4.4.1 influence of the isochuanliansu medication to female Balb/c mouse 4T1 solid tumor
Compared with model group, as shown in table 6, Fig. 6, Fig. 7, the mouse of inoculation 4T1-luc-GFP cell is continuously being given
For ITSN (0.1 mg/kg and 1mg/kg) after 5 weeks, high dose group knurl product is substantially reduced (P < 0.01), shows ITSN high dose pair
4T1 solid tumor is effective, and high dose tumor control rate is more than 30%；As shown in fig. 7, after administration, the death rate of tumor-bearing mice
It is decreased obviously, shows that isochuanliansu has significant anti-triple negative breast cancer activity in vivo.It is used relative to 5-Fu group isochuanliansu
Pharmaceutical quantities are lower, and antitumous effect is close, and show that isochuanliansu of the present invention is antitumor has some superiority on dosage.
Influence of the 6 isochuanliansu medication of table to female Balb/c mouse 4T1 solid tumor
Compared with model group, P < 0.001 * * *
4.4.2 influence of the isochuanliansu medication to female Balb/c mouse 4T1 entity tumor metastasis
Compared with model group, as shown in Fig. 8, Fig. 9, Figure 10, the mouse of inoculation 4T1-luc-GFP cell is continuously being given
After 5 weeks, the rate of transform of high dose group is substantially reduced ITSN (0.1 mg/kg and 1mg/kg).Lung's HE coloration result in Fig. 8 is aobvious
Show, high dose group is significantly reduced relative to the quantity of model group pulmonary nodule stove.Relative to 5-Fu group isochuanliansu dosage
It is lower, and anti-tumor metastasis effect is close, shows that isochuanliansu anti-tumor metastasis of the invention has some superiority on dosage.
Various aspects of the present invention have been described above.However, it should be understood that without departing from spirit of that invention
Under the premise of, those skilled in the art can carry out equivalent change and modification to it, and the change and modification equally fall into the application
The coverage area of appended claims.
Claims (6)
1. application of the isochuanliansu in the drug of preparation prevention and treatment breast cancer.
2. application as described in claim 1, which is characterized in that the isochuanliansu is as unique active constituent for making
The drug of standby prevention and treatment breast cancer.
3. application as described in claim 1, which is characterized in that the breast cancer is triple negative breast cancer.
4. application of the isochuanliansu in the drug of preparation prevention and treatment Metastasis in Breast Cancer.
5. application as claimed in claim 4, which is characterized in that the isochuanliansu is as unique active constituent for making
The drug of standby prevention and treatment Metastasis in Breast Cancer.
6. application as claimed in claim 4, which is characterized in that the breast cancer is triple negative breast cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811280279.8A CN109316483B (en) | 2018-10-31 | 2018-10-31 | Medical application of isotoosendanin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811280279.8A CN109316483B (en) | 2018-10-31 | 2018-10-31 | Medical application of isotoosendanin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109316483A true CN109316483A (en) | 2019-02-12 |
| CN109316483B CN109316483B (en) | 2023-05-26 |
Family
ID=65259812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811280279.8A Active CN109316483B (en) | 2018-10-31 | 2018-10-31 | Medical application of isotoosendanin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109316483B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1476829A (en) * | 2003-07-16 | 2004-02-25 | 中国科学院上海生命科学研究院 | Application of toosendanin as anti-tumor medicine |
| CN102631353A (en) * | 2012-04-26 | 2012-08-15 | 中国药科大学 | Usage of toosendanin in preparation of targeted drug for resisting tumor |
| CN104997793A (en) * | 2015-06-24 | 2015-10-28 | 齐齐哈尔大学 | Application of toosendanin in preparation of drugs used for inhibiting lung cancer cell proliferation and inducting lung cancer cell apoptosis |
-
2018
- 2018-10-31 CN CN201811280279.8A patent/CN109316483B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1476829A (en) * | 2003-07-16 | 2004-02-25 | 中国科学院上海生命科学研究院 | Application of toosendanin as anti-tumor medicine |
| CN102631353A (en) * | 2012-04-26 | 2012-08-15 | 中国药科大学 | Usage of toosendanin in preparation of targeted drug for resisting tumor |
| CN104997793A (en) * | 2015-06-24 | 2015-10-28 | 齐齐哈尔大学 | Application of toosendanin in preparation of drugs used for inhibiting lung cancer cell proliferation and inducting lung cancer cell apoptosis |
Non-Patent Citations (2)
| Title |
|---|
| 董庆海等: "川楝子的研究进展", 《特产研究》 * |
| 邵喜英等: "川楝素对乳腺癌MDA-MB-231细胞增殖的抑制作用", 《江苏医药》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109316483B (en) | 2023-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101007050B (en) | Extract of an traditional Chinese medicine containing isopsoralen, preparation method and use thereof | |
| CN101230003A (en) | Preparation method of salvia miltiorrhiza tanshinoate A | |
| CN104940479A (en) | TCM composition for treating AD diseases | |
| CN101926844B (en) | Stellera chamaejasme L extract and anti-tumor action thereof | |
| CN109316483A (en) | The medical usage of isochuanliansu | |
| CN105777837A (en) | Novel Mogrol derivative monomer | |
| CN101152320B (en) | Traditional Chinese medicine preparation for treating gynecology pelvic inflammatory disease | |
| CN103690535A (en) | Application of demethyleneberberine hydrochloride in preparation of medicament for preventing and/or treating hepatic fibrosis | |
| CN103494813A (en) | Application of hydrochloric acid demethyleneberberine in preparation of drug for preventing and/or treating acute or chronic alcoholic liver disease | |
| CN102526274A (en) | Traditional Chinese medicine for treating chronic hepatitis and hepatic fibrosis | |
| JPS628415B2 (en) | ||
| CN105963307A (en) | Applications of mogrol derivative monomer and composition thereof | |
| CN105708845B (en) | A kind of application of phenylpropanoids and its pharmaceutically acceptable salt in the drug for preparing treatment diseases associated with inflammation | |
| CN104069149A (en) | Method for processing traditional Chinese medicine decoction piece by using bear gall as matrix | |
| CN105663150B (en) | A kind of application of phenylpropanoids and its pharmaceutically acceptable salt in the drug for preparing treatment diseases associated with inflammation | |
| CN101396437B (en) | Anti-gout drop pills of pure traditional Chinese medicine | |
| CN105777821B (en) | Phenylpropanoids and its pharmaceutically acceptable salt and pharmaceutical composition | |
| WO1995023604A1 (en) | Cell growth stimulating compositions containing aloesin | |
| JP5265347B2 (en) | Use of konjac and its extract in formulating pharmaceuticals for the treatment of acute and chronic bronchitis | |
| CN104605344A (en) | Health food for enhancing immunity and preparation method of health food | |
| CN110063960A (en) | 3- hydrogenates the pharmaceutical applications of loose Siberian cocklebur acid B cyanogen methyl esters | |
| CN108743598A (en) | Application of the glucosides tobeimosides first in preparing huge pinocytosis derivant | |
| CN101696166A (en) | Preparation method for danshen root salvianolic acid A | |
| CN113713036A (en) | Application of Diaoxinxuekang in treating alcoholic liver disease | |
| CN106074583B (en) | A kind of application of phenylpropanoids and its pharmaceutically acceptable salt in the drug for preparing treatment diseases associated with inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |